{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:55:29Z","timestamp":1770890129691,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00347-012-2618-8","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T18:07:14Z","timestamp":1354644434000},"page":"1189-1197","source":"Crossref","is-referenced-by-count":12,"title":["Aktuelle Therapieoptionen bei Fr\u00fchgeborenenretinopathie","Current therapeutic options in retinopathy of prematurity"],"prefix":"10.1007","volume":"109","author":[{"given":"T.U.","family":"Krohne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aisenbrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,6]]},"reference":[{"key":"2618_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216","journal-title":"Br J Ophthalmol"},{"key":"2618_CR2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","volume":"22","author":"Autrata","year":"2012","unstructured":"Autrata R, Krejcirova I, Senkova K et al (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687\u2013694","journal-title":"Eur J Ophthalmol"},{"key":"2618_CR3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archopht.123.3.406-a","volume":"123","author":"Averbukh","year":"2005","unstructured":"Averbukh E (2005) The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation. Arch Ophthalmol 123:406 (discussion 409\u2013410)","journal-title":"Arch Ophthalmol"},{"key":"2618_CR4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0161-6420(99)00042-1","volume":"107","author":"Banach","year":"2000","unstructured":"Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324\u2013327 (discussion 328)","journal-title":"Ophthalmology"},{"key":"2618_CR5","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","volume":"90","author":"Carneiro","year":"2012","unstructured":"Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25\u2013e30","journal-title":"Acta Ophthalmol"},{"key":"2618_CR6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3341\/kjo.2011.25.5.305","volume":"25","author":"Choi","year":"2011","unstructured":"Choi J, Kim JH, Kim SJ et al (2011) Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol 25:305\u2013310","journal-title":"Korean J Ophthalmol"},{"key":"2618_CR7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","volume":"8","author":"Compernolle","year":"2002","unstructured":"Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702\u2013710","journal-title":"Nat Med"},{"key":"2618_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471\u2013479","journal-title":"Arch Ophthalmol"},{"key":"2618_CR9","first-page":"197","volume":"109","author":"Deutsche","year":"2012","unstructured":"Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Fr\u00fchgeborenenretinopathie. Ophthalmologe 109:197\u2013204","journal-title":"Ophthalmologe"},{"key":"2618_CR10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early","year":"2003","unstructured":"Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"2618_CR11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1542\/peds.2004-1915","volume":"114","author":"Engle","year":"2004","unstructured":"Engle WA (2004) Age terminology during the perinatal period. Pediatrics 114:1362\u20131364","journal-title":"Pediatrics"},{"key":"2618_CR12","unstructured":"European MAE (2007) Lucentis: scientific discussion (March 14, 2007). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000715\/WC500043550.pdf (Zugegriffen: 21.10.2011)"},{"key":"2618_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00006982-199703000-00009","volume":"17","author":"Hairston","year":"1997","unstructured":"Hairston RJ, Maguire AM, Vitale S et al (1997) Morphometric analysis of pars plana development in humans. Retina 17:135\u2013138","journal-title":"Retina"},{"key":"2618_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cct.2004.03.003","volume":"25","author":"Hardy","year":"2004","unstructured":"Hardy RJ, Good WV, Dobson V et al (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311\u2013325","journal-title":"Control Clin Trials"},{"key":"2618_CR15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00006982-200410000-00011","volume":"24","author":"Hartnett","year":"2004","unstructured":"Hartnett ME, Maguluri S, Thompson HW et al (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753\u2013757","journal-title":"Retina"},{"key":"2618_CR16","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1242\/dev.02385","volume":"133","author":"Hashimoto","year":"2006","unstructured":"Hashimoto T, Zhang XM, Chen BY et al (2006) VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133:2201\u20132210","journal-title":"Development"},{"key":"2618_CR17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0161-6420(98)91023-5","volume":"105","author":"Hinz","year":"1998","unstructured":"Hinz BJ, Juan E de Jr, Repka MX (1998) Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology 105:1827\u20131830","journal-title":"Ophthalmology"},{"key":"2618_CR18","doi-asserted-by":"crossref","unstructured":"Hoerster R, Muether P, Dahlke C et al (2012) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol [Epub ahead of print]","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"2618_CR19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006","journal-title":"Arch Ophthalmol"},{"key":"2618_CR20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"key":"2618_CR21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00347-008-1841-9","volume":"105","author":"Jandeck","year":"2008","unstructured":"Jandeck C, Kellner U, Lorenz B et al (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955\u2013963","journal-title":"Ophthalmologe"},{"key":"2618_CR22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"Krohne","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508\u2013512","journal-title":"Am J Ophthalmol"},{"key":"2618_CR23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682\u2013686","journal-title":"Am J Ophthalmol"},{"key":"2618_CR24","doi-asserted-by":"crossref","unstructured":"Laws DE, Haslett R, Ashby D et al (1994) Axial length biometry in infants with retinopathy of prematurity. Eye (Lond) 8(Pt 4):427\u2013430","DOI":"10.1038\/eye.1994.101"},{"key":"2618_CR25","first-page":"488","volume":"225","author":"Lorenz","year":"2011","unstructured":"Lorenz B (2011) Kommentar: Anti-VEGF-Einsatz gut abw\u00e4gen. Klin Monatsbl Augenheilkd 225:488\u2013490","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"2618_CR26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00417-009-1077-7","volume":"247","author":"Lorenz","year":"2009","unstructured":"Lorenz B, Spasovska K, Elflein H et al (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251\u20131262","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2618_CR27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"Lu","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779\u2013786","journal-title":"Cancer Chemother Pharmacol"},{"key":"2618_CR28","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"},{"key":"2618_CR29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","volume":"94","author":"Matsuyama","year":"2010","unstructured":"Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215\u20131218","journal-title":"Br J Ophthalmol"},{"key":"2618_CR30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"2618_CR31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","volume":"118","author":"Moshfeghi","year":"2011","unstructured":"Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118:1227\u20131228","journal-title":"Ophthalmology"},{"key":"2618_CR32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/bjo.2011.203125","volume":"96","author":"Muether","year":"2012","unstructured":"Muether PS, Kribs A, Hahn M et al (2012) No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort. Br J Ophthalmol 96:400\u2013404","journal-title":"Br J Ophthalmol"},{"key":"2618_CR33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0161-6420(01)01017-X","volume":"109","author":"Ng","year":"2002","unstructured":"Ng EY, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928\u2013934 (discussion 935)","journal-title":"Ophthalmology"},{"key":"2618_CR34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.123.3.311","volume":"123","author":"Palmer","year":"2005","unstructured":"Palmer EA, Hardy RJ, Dobson V et al (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311\u2013318","journal-title":"Arch Ophthalmol"},{"key":"2618_CR35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bjo.2009.162156","volume":"94","author":"Patel","year":"2010","unstructured":"Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107\u20131109","journal-title":"Br J Ophthalmol"},{"key":"2618_CR36","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ophtha.2004.06.021","volume":"111","author":"Prenner","year":"2004","unstructured":"Prenner JL, Capone A Jr, Trese MT (2004) Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 111:2271\u20132273","journal-title":"Ophthalmology"},{"key":"2618_CR37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327\u2013333","journal-title":"Am J Ophthalmol"},{"key":"2618_CR38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajo.2007.01.017","volume":"143","author":"Sears","year":"2007","unstructured":"Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810\u2013813","journal-title":"Am J Ophthalmol"},{"key":"2618_CR39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","volume":"117","author":"Section","year":"2006","unstructured":"Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572\u2013576","journal-title":"Pediatrics"},{"key":"2618_CR40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archopht.1997.01100160440008","volume":"115","author":"Seiberth","year":"1997","unstructured":"Seiberth V, Linderkamp O, Vardarli I (1997) Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 115:1270\u20131275","journal-title":"Arch Ophthalmol"},{"key":"2618_CR41","doi-asserted-by":"crossref","unstructured":"Wilkinson AR, Haines L, Head K et al (2009) UK retinopathy of prematurity guideline. Eye (Lond) 23:2137\u20132139","DOI":"10.1038\/eye.2008.128"},{"key":"2618_CR42","doi-asserted-by":"crossref","unstructured":"Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931\u2013933","DOI":"10.1038\/eye.2009.156"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2618-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-012-2618-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2618-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T15:39:08Z","timestamp":1562427548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-012-2618-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1007\/s00347-012-2618-8","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}